Trial Profile

A Phase 1b Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide or in Combination With Pomalidomide for Multiple Myeloma

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 17 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs JNJ 79635322 (Primary) ; Daratumumab; Pomalidomide
Indications Multiple myeloma
Focus Adverse reactions
Sponsors Janssen Research & Development

Most Recent Events

13 Feb 2026 Planned End Date changed from 20 Jun 2028 to 23 Nov 2028.
24 Dec 2025 Planned End Date changed from 31 Mar 2028 to 19 Nov 2027.
24 Dec 2025 Planned primary completion date changed from 31 Mar 2028 to 20 Jun 2028.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com